Carl June retweeted
Can AI help identify targets for living therapies?
We grounded frontier LLMs with patient tumor data and public knowledge bases, then tested their ability to nominate targets. GPNMB rose to the top—and GPNMB CAR T cells showed promise across blood and solid-tumor models.
In the latest issue! AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy dlvr.it/TTHFjJ
Carl June retweeted
Heading to the @ISCTglobal Annual Meeting in Dublin? Come visit us at the Penn Medicine Clinical Cell and Vaccine Production booth 2505 1st Floor The Liffey across from ISCT Hub and meet our Facilities, Analytics, Operations, Regulatory and Manufacturing Experts.
We’ve built an integrated platform designed to move programs from discovery into first-in-human studies with rigor, speed, and quality.
What differentiates this model is not a single capability, but the integration:
• cGMP Phase I manufacturing in 15 ISO 7 suites
• Process development and scale-up for complex cell therapies
• End-to-end QC analytics and FACT-aligned quality systems
• Advanced correlative science, including multiparameter flow, molecular assays, and spatial biology
• Deep experience translating across oncology and immune diseases
We are actively looking to partner with biotech, pharma, and academic groups in three areas:
• Manufacturing: early-phase and first-in-human CGT production
• Process development: improving robustness, scalability, and comparability
• Analytics and correlative studies: biomarker strategies that inform mechanism, response, and durability
If you are advancing a program and need a partner who understands both the science and the realities of clinical translation, we should connect to build the next generation of cell and gene therapy together. #celltherapy #genetherapy #innovation #immunotherapy
Carl June retweeted
Check out our latest paper, published @NatureComms. We show that STING activation induces IL18 secretion and thereby enhances CAR T function. Great collaboration between @CarlHJune lab and James Chen @UTSWMedCenter.
@PennMedicine @PennMDForum @PennPPA
nature.com/articles/s41467-0…
wonderful work from @sonia guedan, former post doc. From her lab in Barcelona,j ust published in Nature Communications doi.org/10.1038/s41467-024-4…
Anti-competitive practices of 10X genomics have forced Nanostring into chapter 11 restructuring. 10x has initiated litigation against not only Nanostring but also Vizgen, Curio Biosciences and Parse Biosciences. See below for more information:
(genengnews.com/topics/bioper…)
(genengnews.com/topics/omics/…)
xitter.cf/sixers/status/17499155…
My lab in Spotlight at 76ers historic game when Embiid scored 70 points and set a franchise record for the 76ers. @PennMedicine
🩺 @PennMedicine spotlight:
last night we recognized Dr. Carl June, the Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania.
Dr. June is joined by members of the June Laboratory, which provides researchers with the tools they need to translate laboratory insights into safe and effective cancer therapies. The June Lab has many faculty researchers focused on developing ways to enhance the ability of the natural immune system to recognize and eliminate tumor cells.
Carl June retweeted
Tons of promising work using CAR T cells beyond cancer. Already showing signs of efficacy in early clinical reports. Check out our review in @Nature of this rapidly evolving field!
W/ @AranyLab @BaurLab @jonepstein1 @carlhjune
nature.com/articles/s41586-0…
thrilled that Bruce Levine to receive PMWC 2023 Pioneer Award. linkedin.com/posts/pmwcintl_…
Carl June retweeted
What can happen when #CARTcell Therapy Meets #ClonalHematopoiesis? @CarlHJune puts multiple scenarios InFocus @BCD_AACR
aacrjournals.org/bloodcancer…
Carl June retweeted
10 years ago Emily Whitehead’s family got the news that she was cancer free. We wondered whether these #carTcells could keep her in remission and cure her disease without BMT. Now we know.
10 years from this transformative clinical experience, 5 years from @FDA approval.
Today, Emily is 10 years cancer free!
With this important milestone reached, we can now also celebrate that Emily is CURED. bit.ly/ewf-10yearscured
#WeBelieve
#ActivateTheCURE
#10YearsofCART
Carl June retweeted
Was $NVS BELINDA #CARTCell #tcellrx vs SOC Phase III failure in #lymphoma due to manufacturing?? If 2% serum used in ex vivo media, acknowledged 2B inferior to 5% in #ASH21 poster 1768. 5% only used from end 2020 onwards. #lymsm #immunotherapy ash.confex.com/ash/2021/webp…
I've had it with gun violence. The husband of my 3rd cousin was shot and is now hemiplegic
in a senseless drive by shooting.
Yakima man hit in drive-by shooting while working in yard in Barge-Chestnut area | Crime And Courts | yakimaherald.com yakimaherald.com/news/crime_…
Carl June retweeted
Visionary philanthropist Barbara Netter has made a profound impact on science & medicine. With late husband Edward, they founded @ACGTFoundation whose mission is to fund #celltherapy #genetherapy #research to empower pioneering and innovative scientists phillyfightscancer.org/2020/…
AT 10 years I think we can say our first CAR T patient is cured.
#OTD celebrating 10 years since 1st CAR19 #Tcell infusion @PennMedicine We thank all patient #Heroes for volunteering to advance #cancer #Immunotherapy 🙏🦸♂️🦸♀️nytimes.com/2011/09/13/healt…
Carl June retweeted
We are so lucky to have you at the helm! Thanks for the leadership, inspiration, vision and steady hand in these challenging times.
Today marks my first anniversary as CEO of the University of Pennsylvania Health System @PennMedicine. It is my singular honor to lead the nation’s best health system. Given the enormous challenges we faced this year, I salute your unwavering commitment to our mission!